

Aptamer-based approaches for *in vitro* molecular detection of cancer

Hadi Bakhtiari¹, Abbas Ali Palizban¹, Hossein Khanahmad², and Mohammad Reza Mofid^{1,*}

¹Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I. R. Iran.

²Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, I. R. Iran.

Abstract

Cancer is typically associated with abnormal production of various tumor-specific molecules known as tumor markers. Probing these markers by utilizing efficient approaches could be beneficial for cancer diagnosis. The current widely-used biorecognition probes, antibodies, suffer from some undeniable shortcomings. Fortunately, novel oligonucleotide-based molecular probes named aptamers are being emerged as alternative detection tools with distinctive advantages compared to antibodies. All of the existing strategies in cancer diagnostics, including those of *in vitro* detection, can potentially implement aptamers as the detecting moiety. Several studies have been performed in the field of *in vitro* cancer detection over the last decade. In order to direct future studies, it is necessary to comprehensively summarize and review the current status of the field. Most previous studies involve only a few cancer diagnostic strategies. Here, we thoroughly review recent significant advances on the applications of aptamer in various *in vitro* detection strategies. Furthermore, we will discuss the status of diagnostic aptamers in clinical trials.

Keywords: Aptamer; Biosensor; Cancer detection; Tumor marker.

1. INTRODUCTION

Cancer, as one of the most important health problems, is mainly originated from some genetic or epigenetic alterations and typically represented as uncontrolled cell growth with abnormal production of various molecular products (1,2). Probing cancer-specific markers called tumor markers, which are mainly resulted by the alterations could be beneficial for cancer diagnosis and management. Therefore, utilization of efficient approaches for punctual and accurate tumor marker recognition is of great clinical significance (3).

The ability of the conventional tumor marker recognition strategies is restricted by the lack of proper detecting agents. Current widely-used biorecognition probes, antibodies, suffer from limited chemical modification, easy denaturation and degradation, animal-dependent production, poor penetration (due to large size), and immunogenicity (4,5). Fortunately, another class of molecular probes named aptamers, which can efficiently recognize a range of

targets from small molecules to the whole intact cells, are being emerged as alternative detection tools with distinctive properties (5-7). Aptamers are typically obtained from an oligonucleotide (single-stranded DNA or RNA) library using a cyclic selection process known as the systematic evolution of ligands by exponential enrichment (SELEX) (8-11). The target binding occurs through their three-dimensional structure with reasonable affinity and specificity at low target concentrations. Their binding affinity is comparable to that of antibodies (9,12,13).

There is a growing interest in aptamer investigations. A search on Science Direct database (<https://www.sciencedirect.com/>) on January 10th, 2020, showed a progressive increase in the number of the review or research articles, in which their keywords, title or abstract include the word "aptamer" since the year 2000 (Fig. 1).

Access this article online



Website: <http://rps.mui.ac.ir>

DOI: 10.4103/1735-5362.283811




Fig. 1. Number of articles published each year in the field of aptamer since 2000. The result of a search on Science Direct database on 10 January 2020 presenting the number of the review or research articles, which their keywords, title or abstract include the word (A) “aptamer”, and (B) “aptamer and biosensor”, have progressively increased since 2000.

Several detection strategies have been introduced to date to detect oncological biomarkers both *in vitro* and *in vivo*. These strategies include tissue-related marker detection, enzyme-linked assays, flow cytometry, biosensing, and bioimaging. Aptamers could be used as the detection moiety in all of these approaches. However, the *in vitro* application of aptamers is more applicable since oligonucleotides would be degraded by various nucleases available in living systems. In some cases, the use of aptamer in place of traditional probes has certain advantages. For instance, because of the nucleic acid nature, immobilized aptamer probes in the plates of enzyme-linked assays could be simply reused for several experiments (14-16). In the case of biosensing, the conformational change of aptamers after binding to their intended targets makes these nucleic acid-based probes an appropriate tool for switchable systems.

In this study, we will comprehensively review a variety of aptamer-based detection techniques used to visualize and quantify tumors. However, our focus will be on recent advances in use of aptamer probes for *in vitro* detection of various cancers.

2. TUMOR-SPECIFIC APTAMERS FOR IN VITRO DETECTION OF CLINICAL SAMPLES

Aptamers have been extensively used *in vitro* to detect a wide variety of cancers. There are numerous reliable tumor-markers in cancer tissues, on circulating tumor cells (CTCs), and soluble in the bloodstream of patients, which

can be detected utilizing appropriate probes for a dozen of purposes such as early cancer diagnosis, molecular monitoring of treatment progression, prognosis, detection of invasion and metastasis, and biochemical monitoring of recurrence.

Quantification of nucleotide aptamer can be easily achieved by quantitative real-time polymerase chain reaction (qRT-PCR). However, since aptamers could be easily chemically manipulated, various signaling tools including fluorescent agents, biotin/streptavidin-horseradish peroxidase (HRP) conjugates, and electro-chemicals could be implemented in aptamer selection techniques to give accurate and sensitive quantitative probes (17). In this regard, researchers developed a variety of aptamer-based technologies for *in vitro* cancer diagnosis. Traditional quantifying strategies that have been adjusted to implement nucleotide aptamers as the targeting moiety consists of aptahistochemistry, aptamer-based enzyme-linked immunosorbent assay (ELISA), qRT-PCR, and aptamer-based flow cytometry. More recently, researchers have offered various innovative platforms to enhance sensitivity and accuracy of target detection including a variety of aptamer-based molecular biosensing techniques (18,19).

3. APTAMER APPLICATION IN TRADITIONAL CANCER DETECTION METHODS

The use of aptamers as a traditional *in vitro* cancer diagnostic tool has been frequently

reported in numerous studies. These include the detection of tumor markers on histopathological tissue sections and those present in circulation.

3.1. Tissue-marker detection (aptahistochemistry analysis)

Along with the hematoxylin and eosin (H&E) staining of tumor tissue slides as the gold standard of cancer detection, histopathological immunostaining is also used to improve the sensitivity of recognition, predict prognosis, and determine subtypes of various cancers. In comparison with the application of antibodies in immunostaining of formalin-fixed paraffin-embedded tissue sections, aptamers are smaller, therefore penetrate more easily and efficiently (20). It has been also reported that the nonspecific signal of the necrotic area is efficiently omitted using aptamer probes (20). Visualization is usually carried out using 3'-diaminobenzidine tetrahydrochloride, as a horseradish peroxidase substrate, or fluorophores-based techniques (21,22). Fortunately, both of them are simply applicable in aptamer-based staining of tissue slides, because of the adaptable nature of nucleotide aptamers (4,5). As shown in Fig. 1, an increasing number of studies have reported the use of aptamer in histopathological staining of tumor sections.

In an investigation, Wang *et al.* generated a fluorescent dye-labeled aptamer named Wy-5a against prostate cancer, which could efficiently differentiate high-risk groups with metastasis from benign prostatic hyperplasia (22). In another study, Duan *et al.* introduced a fluorophore Cy5-labelled-aptamer having excellent selectivity for recognition of the metastatic prostate cancer (23). In 2017, Huang *et al.* produced a Cy5-labelled-aptamer against prostate cancer, capable of binding to its target in the microenvironment of tissue sections (24). In another work, Stuart *et al.* developed a biotin-labeled vitronectin binding aptamer to stain human breast cancer tissue slides. They also realized that in contrast to the monoclonal antibody which preferentially binds to the extracellular matrix and vessel walls, where vitronectin can become multimerized, the aptamer directly binds to tumor cells, with

much lower binding to extracellular matrix (25). Shigdar and her colleagues reported their isolated aptamer against epithelial cell adhesion molecule, a type I glycosylated membrane protein, which is more sensitive and specific than existing antibodies for the detection in breast cancer tissue slides. This aptamer showed no non-specific signal with tissues negative for expression of epithelial cell adhesion molecule (25). Using biotinylated anti-estrogen receptor aptamers and HRP-streptavidin, Ahirwar *et al.* reported their successful attempt in estrogen-receptor (ER)-positive breast cancer tissues (26). The results demonstrated that their aptamer-based histopathological tissue staining can be used efficiently for proper grading of ER α expression (26). In another study by using 3'-diaminobenzidine tetrahydrochloride and HRP, Han *et al.* developed an aptamer against matrix metalloproteinase 2 and confirmed its potential in binding to the target on tissue sections (21). Yuan *et al.* selected and labeled (with fluorescent dye Cy5) an aptamer with the ability to distinguish lymph node tissue sections with colorectal cancer metastasis using cell-SELEX on metastatic colorectal cancer cell lines (27).

3.2. Detection of circulating markers

Detection of circulating tumor markers has great importance in management of the disease because cancer tissues are not always accessible. Sometimes, cancer cells are located in remote parts of the body making them unreachable (28). Also, the removal of tissue samples *via* a biopsy or surgical procedure is considered an invasive procedure with noticeable post-operational complications (29). In addition, repeated sampling is almost impractical; therefore, histopathological-based methods are not appropriate for monitoring of cancer progression or treatment. Unlike tissue-specific markers detected in histopathological immunostaining, some circulating tumor markers could be spotted at the early stages of cancer, allowing early detection and intervention (30,31).

Using appropriate aptamers, circulating tumor-markers including soluble proteins, analyst, and CTCs can be effectively spotted

through a dozen of methods converting detection to an assessable signal. These strategies include qRT-PCR, ELISA, flow cytometry, and molecular biosensing.

3.2.1. qRT-PCR

Quantification of nucleic acids is simply and reliably achievable using qRT-PCR (32,33). The exact amount of the initial nucleic acids is calculated using a standard curve drawn with known concentrations of the intended DNA (34). Consequently, by implementing this technique, it is possible to directly quantify a nucleotide aptamer which bind to the target of interest. In this way, the identified amount of each aptamer will be proportional to the amount of its specific target, excluding the need for expensive labeling of the detection aptamer. However, despite the use of this method in other areas (35-39), few studies on cancer have been performed in this regard (40,41).

In a study, Li *et al.* could simply detect serum biomarkers of patients with lung cancer using magnetic carboxyl agar beads as the aptamer selection method and qRT-PCR as the quantification strategy. They showed that their pioneering aptamer-based system led to a much more sensitive diagnosis than the conventional antibody-based diagnostic methods (40). In a recent attempt to select reliable DNA aptamer against serum of colorectal cancer patients, Li *et al.* implemented qRT-PCR in the selection procedure, the assessment of the affinity and selectivity, and bio-detection in human blood samples (41).

3.2.2. Aptamer-based enzyme-linked assay

ELISA has been considered as a reliable quantitative assay in traditional cancer diagnostics, which uses antibody probes as the tumor marker recognizing moiety. Introducing nucleic acid aptamers as novel molecular recognition agents with some superior features comparing to traditional antibodies led to development of an aptamer-based ELISA named enzyme-linked aptamer sorbent assay (ELASA). Like the original antibody-based assay, ELASA can be performed in various modalities including direct, indirect and sandwich assay (Fig. 2). In addition to its general advantages, the specific benefit of this method is that the immobilized capturing

aptamer can be simply reused by heating and refolding after each experiment (42). Also, there are a variety of innovative ways other than heating to make the plates practically reusable, including the use of chaotropic reagents, surfactants, or chelating agents (14-16). To validate a DNA aptamer-based sandwich ELISA, Lee *et al.* succeed in recognizing a well-known tumor-marker named lipocalin-2 (LCN2) in the serum of patients with hepatocellular carcinoma. This assay platform benefits from a sandwich pair of aptamers including an immobilized NH₂-modified capture-aptamer and an HRP-labeled reporter-aptamer. The researchers claimed that the developed assay platform is capable of quantifying low-medium abundance tumor-markers presented in patient serum ranging from ng to µg/mL (43). Ahirwar *et al.* established an aptamer-based ELISA to show the potential of their proper selected aptamer in probing target of interest related to human breast cancer (26). In another study, Ferreira *et al.* successfully designed an aptamer-antibody sandwich ELISA to identify and quantify mucin 1 (MUC1) in solutions; therefore they could establish innovative diagnostic tools against this biomarker for detection of various epithelial tumors (44). Two innovative aptamer sandwich-based microfluidic ELISA assays for recognizing free prostate specific antigen (FPSA) in patients with prostate cancer were developed by Jolly *et al.*, where a DNA aptamer was used as the capturing probe and an antibody or a lectin was utilized as the detecting agent to quantify the target (FPSA) by chemiluminescence (45).




Fig. 2. Schematic picture of enzyme-linked aptamer sorbent assay. (A) Direct target-aptamer ELASA; (B) sandwich aptamer-target-aptamer ELASA; (C) sandwich aptamer-target-antibody ELASA; and (D) sandwich antibody-target-aptamer ELASA, Enzyme-linked aptamer sorbent assay; HRP, horseradish peroxidase.

In a recent study, Zhu *et al.* used an enzyme-labeled anti-MUC1 aptamer to establish an aptamer-based sandwich configuration of ELASA. In the proposed assay, the immobilized aptamer is fabricated on a gold electrode surface and the reporting aptamer is conjugated with HRP (46). In another study, Kavosi *et al.* utilized sandwich-type enzyme-linked aptamer incorporation with electrochemical biosensors and gold nanoparticles as a triple signal amplification method to PSA (47).

3.2.3. Aptamer-based flow cytometry

Fluorophore labeled aptamers that are designed against cell surface tumor markers can be simply measured using flow cytometry technique. By implementing the cell-SELEX technique, our group validated a fluorophore labeled ssDNA aptamer against the B-lymphocyte antigen (CD20). The expression of CD20 is various in different types of acute lymphoblastic leukemia (ALL), which helps to differentiate various types of the disease including B-cell precursor-ALL (30-50%), and mature B-cell ALL (80-90%). Using flow cytometry and fluorescein isothiocyanate-labeled probes, we could ultimately distinguish B-cell with different expression of CD20 in real patient specimens of bone marrow (48). In another work on isolating DNA aptamer probes by a novel pipeline approach, Yang *et al.* could successfully define the phenotype of normal hematopoietic cells and acute myelogenous leukemia (AML) in patient samples by flow cytometry (49). In order to distinguish different types of cells (T- and B-cells) in patients with blood cancer, Shangguan *et al.* could develop a set of aptamer probes based on molecular differences between cells using cell-SELEX technique. Assessed by flow cytometry, the isolated aptamers with fluorescein isothiocyanate label could specifically recognize various cells in bone marrow aspirates, proposing specific tools for cancer detection and therapy (50). In an attempt made to generate a multivalent aptamer probe specifically binding to the B-cell receptors in patients with leukemia and lymphoma, Mallikaratchy *et al.* employed flow cytometry on tumor cell lines and real clinical specimen to

show the ability of their selected aptamer in bivalent staining of the target of interest. They reported that their obtained bivalent aptamers could distinguish between patients with non-B-cell malignancy, chronic myeloid leukemia, and those with B-cell malignancy, B-chronic lymphocytic leukemia, and hairy cell leukemia (51). In another study, Sefah *et al.* reported a properly isolated aptamer obtained using the cell-based selection technique with the ability to target AML cells in both cell culture and real clinical samples by flow cytometric assay. They also developed two other aptamers recognizing targets related to differentiation of monocytes. Their results showed the potential of cell-SELEX and flow cytometry in recognizing subclasses of AML, and introduced new potent cell-membrane markers (52). Tan *et al.* introduced an innovative method based on aptamer-modified fluorescent silica nanoparticles to specifically target leukemia cells. The principle of the strategy is the formation of amid links between amino groups of amino-labeled aptamers and the carboxyl group of the carboxyl-modified fluorescent silica nanoparticles. Their final assessment was through flow cytometry and fluorescence microscopy to show the sensitivity and specificity of the isolated probes (53). Using flow cytometry analysis, Zhang *et al.* showed the power of the Cy5-labeled RNA aptamer targeting CD30 in detecting anaplastic large cell lymphoma cells and Hodgkin's lymphoma cell lines both in cultured cells and mixed cell specimens (54).

3.2.4. Aptamer-based detection of CTCs

Tsai *et al.* proposed an integrated microfluidic system based on aptamer technology to establish an authentic way to spot ovarian CTCs which have extremely low concentration in peripheral blood circulation. The first step of the procedure is elimination of erythrocytes followed by depletion of white blood cells. Then the ovarian CTCs could be captured using appropriate aptamers. The authors claimed that their innovative approach yields a higher recovery rate for CTCs than the traditional methods using antibodies (55). Zheng *et al.* introduced a novel barcode particle technology using various dendrimer-amplified

aptamer probes in order to capture a wide variety of CTCs in the peripheral bloodstream, promising new perspectives in cancer detection using CTCs (56). Zamay *et al.* developed specific aptamer probes which were capable of detecting CTCs in peripheral blood of patients with metastatic lung cancer. They claimed that the aptamer could be rapidly and specifically generated for each individual patient, opening up the opportunity of personalized diagnostics (57).

In an investigation, Li *et al.* developed an interesting method taking advantage of aptamer-functionalized hydrogels to catch CTCs and restriction endonucleases to efficiently release them (approximately 99%) (58). In another work on patients with non-small cell lung cancer, a microfluidic assay was successfully set up based on a cocktail of synergistic aptamers. Implementing aptamer cocktails enhanced the performance of CTCs catch compared to solitary probes (59).

4. VARIOUS TYPES OF SENSING STRATEGIES IN APTAMER BIOSENSORS

Biosensing technology is emerging as an important strategy to visualize and quantify biochemical targets of interest. A biosensor, that calculates the concentration of a specific analyte by converting the molecular detection event into a computable signal, can be attached with various high-affinity bioprobes allowing efficient detection of intended biomolecules

(18). Biosensors commonly composed of the following components: an analyte detecting part named bioreceptor, a signal transducer part converting detection of the analyte into a computable signal, electronic part for signal amplification, and a display part that visualize the outcomes (18).

Using antibodies as traditional detecting agents, several studies have been done on biosensors aimed at cancer detection, most of them based on the sandwich detection system (19,60). According to the general advantages of aptamer probes, recent studies have tried to replace antibodies with their aptamer counterparts. In addition, the conformational change of aptamers after binding to their intended targets makes these nucleic acid-based probes an appropriate tool for developing switchable biosensing systems. Various sensing technologies including electrochemical (using impedimetric, voltametric, potentiometric, amperometric, electrochemiluminescence, and *etc.*), and optical sensors (using fluorophores, quantum dots, surface plasmon resonance, intercalating dyes, bioluminescent, and *etc.*) along with a variety of nanomaterials like metallic nanoparticles, graphene, graphene oxide, carbon nanotubes, and nanowires of different agents have been sophisticatedly incorporated to set up authentic bio-recognition tools to date(18,19). Schematic views of aptamer-based biosensing are depicted in Figs. 3 and 4.




Fig. 3. Schematic picture of electrochemical biosensing. The interaction between aptamers and targets impact electron transfer to the gold nanoparticle coated electrode, making signals proportional to the detected targets. (A) Conjugated aptamer-based approach in electrochemical biosensing and (B) free aptamer-based approach in electrochemical biosensing. HRP, Horseradish peroxidase; GD, glucose dehydrogenase; et, electron transfer; Au, gold; $\text{Fe}(\text{CN})_6^{4/3-}$, Ferrocyanide.




Fig. 4. Schematic picture of fluorescence biosensing. Various types of fluorescence biosensors are depicted as described in the picture. (A) Simple fluorophore-labeled aptasensors; (B) fluorophore/quencher-based aptasensors; (C) gold nanoparticle/fluorophore-labeled aptasensors; (D) quantum dot aptasensors; and (E) magnetic nanoparticle/fluorophore-labeled aptasensors.

4.1. Electrochemical aptamer-based biosensors

In 2020, Zhou *et al.* introduced an electrochemical impedance sensor based on free aptamers, gold electrodes and ferrocyanide ($\text{Fe}(\text{CN})_6^{4-}$) to detect serum CD44 biomarkers in the range of 0.1-1000 ng/mL with a detection limit of 0.087 ng/mL (61). In another study, Safavipour *et al.* implemented TiO_2 nanotubes-reduced graphene oxide (TiO_2 nanotube-rGO) to obtain MUC1 aptamer-based electrochemical biosensor to recognize breast cancer cells (MCF-7) (62). Presenting an electrochemical platform by gold electrodes and using a HER2-specific DNA aptamer, Sunil K. Arya *et al.* launched a powerful electrochemical aptasensor for breast cancer classification. Their developed aptasensor was able to detect human epidermal growth factor receptor 2 (HER2) from 1 pM to 10 nM in unprocessed patient serum, promising future success in developing similar aptasensors for other possible protein tumor markers (63). In another study, a glassy carbon electrode (GCE) containing multiwall carbon nanotubes and poly glutamic acid was used by Yazdanparast *et al.* to set up a dual aptamer sandwich sensor detecting the breast cancer cell line, MCF7. The immobilizing probe was a MUC1 detecting aptamer and the recognizing part was an MCF7-binding aptamer with a silver

nanoparticle label. In order to follow the electrochemical signal of the silver nanoparticles, the obtained sandwich electrochemical system used differential pulse anodic stripping voltammetry (64). Reporting a bipolar electrode system that benefits from electrochemiluminescence technology and using two aptamers detecting nucleolin, Motaghi *et al.* were able to sensitively detect cancer cells in the acceptable linear range of 10-700 cells and selection limit of 10 cells (65). In an attempt to develop an accurate and efficient platform capable of tumor-marker detection, Nie *et al.* implemented electrochemiluminescence assay along with a non-enzymatic amplification and aptamer-triggered emitter release strategy. Therefore, they were able to improve the analytical accuracy of breast cancer biomarker recognition (66). Amouzadeh Tabrizi *et al.* could effectively capture and release promyelocytic leukemia cells (HL-60) from real patient serum using a novel nanomotor containing manganese oxide nanosheets-polyethyleneimine with nickel/gold nanoparticles ($\text{MnO}_2\text{-PEI/Ni/Au}$) and HL-60 specific aptamers. The suggested electrochemical platform was able to detect cancer cells in the acceptable linear range of $25\text{-}5 \times 10^5$ cells and the selection limit of 250 cells (67). Preparing the first complementary metal oxide semiconductor (CMOS) biosensor for electrochemical tumor detection *via* a peptide

aptamer-based microneedle exclusively binds to vascular endothelial growth factor (VEGF), Song *et al.* could directly spot the biomarker in unprocessed patient blood. The presented system, which benefits from a two-step capacitance-to-digital converter visualizing small changes in VEGF concentrations, could efficiently spot VEGF in the range of 0.1 to 1000 pM (68). In another study, an elaborate electrochemical sandwich-based aptasensor containing tetrahedral DNA nanostructures-aptamers on the outside of gold electrode as the capturing probe, the nanozyme Mn_3O_4 with the second aptamer as the first amplifying nanoprobe, and an HRP/complementary DNA (cDNA) nanoprobe to further intensify the signal was generated to specifically and sensitively detect the breast cancer HER2 biomarker. Results demonstrated that the proposed platform can operate in a wide linear concentration range (0.1-100 ng/mL) (69). Implementing gold nanoparticles, platelet-derived growth factor specific aptamer, and electrochemical measurement technology, Hasanzadeh *et al.* established an aptasensor assay capable of recognizing MCF7 breast cancer cell line. The researchers claimed that the developed electrochemical biosensor is applicable in straight patient plasma specimens (70). A complimentary list of similar works is presented in Table 1.

4.2. Fluorescent aptamer-based biosensors

A combination of cell-SELEX derived aptamer and gold nanoparticles were used to develop a strip biosensor against Ramos cancer cells in real human bloodstream by Liu *et al.* The proposed strip biosensor system provided a promising fast quantitative way to detect circulating tumor cells with a reasonable sensitivity (103). In an investigation, Bayat *et al.* constructed a fluorescent aptamer-based biosensor for detection of CD70-positive tumor cells and isolated a DNA aptamer against tumor marker CD70 (104). Gedi *et al.* designed an on-chip aptamer-antibody based cancer-detecting platform containing a CA125-specific DNA aptamer, an immobilized antibody against CA125 and a three-dimensional network of carbon nanotubes. The authors demonstrated that this on-chip platform is superior to other

approaches like graphene oxide-based and ELISA assays (105). An aptamer gold-nanostructures immunochromatographic strip was introduced in a study aimed at quantifying a new tumor marker named N-glycolylneuraminic acid by Gong *et al.* in 2018. The platform provided rapid and sensitive detection of the target of interest with a quantitative detection limit of 5.38 ng/mL (106). An innovative method based on bifunctional aptamer and catalytic hairpin assembly was designed and successfully applied by Liu *et al.* to efficiently detect cancer cells in clinical specimens. Division of the fluorophores from their related quenchers in the presence of captured cancer cells leads to signal production. The measurement of targets in real patient samples did not need any additional process (107). Luo *et al.* established a switchable cytosensor using hairpin DNA, including MUC1 aptamer and initiation strand of the catalytic hairpin assembly-mediated Y-junction nicking enzyme assisted signal amplification circuits to identify MUC1 positive breast cancer cells (MCF-7) (108). Using photoactive knowledge and aptamer-based recognition technology, Mazhabi *et al.* set up a novel photoelectrochemical cytosensor identifying HeLa cervical cancer cell lines with a limit of detection of 5 cells/mL. In the proposed assay, g-C₃N₄-AgI nanocomposites were utilized as light-sensitive resources (109). In another work, molybdenum disulfide (MoS_2) nano sheets and carcinoembryonic antigen (CEA)-specific aptamers with fluorescence labels were used by Zhao *et al.*, to construct a fluorescent biosensor detecting CEA tumor marker in the patient specimens. Following probe-target interaction, a conformational change will be occurred leading separation of aptamer from the surface of the nanosheets and then the production of the fluorescence signal. The linear range of detection was reported to be 100 pg to 100 ng/mL with the limit of 34 pg/mL (110). In an observational case-control clinical trial started in June 2015, 100 patients with bladder cancer are being monitored using a colorimetric aptamer biosensing approach to follow bladder cancer biomarkers (111). A complimentary list of similar works is presented in Table 1.

Table 1. Complementary list of studies describing aptamer-based biosensors in cancer diagnostics.

Target	Transducer	Electrode/ Nanoparticle	Aptamer- label	Refs
Mucin 1 (MUC1)	Surface Plasmon Resonance	Au nanoparticles		(71, 72)
	Surface Plasmon Resonance	Magnetic nanoparticle		(73)
	Electrochemiluminescence	Au nanoparticles-deposited glassy carbon electrode (depAu/GCE)		(74)
	Differential pulse voltammetry (DPV)	negatively charged ITO electrode		(75)
VEGF	Surface Plasmon Resonance	Carboxyl-coated polystyrene microsphere		(76)
	Cyclic voltammograms (CVs) /amperometric	Glassy carbon electrode (GCE)	Ag/Pt bimetallic nanoclusters	(77)
	Electrochemiluminescence/electrochemical impedance spectroscopy (EIS)	Cys-CdS:Eunanocrystals (NCs) modified GCE		(78)
PDGF	Potentiometric a field-effect transistor (FET)	Carbon Nanofiber Carboxylatedpolypyrrol e-coated hybrid carbon nanofibers (CPMCNFs)		(79)
	Linear sweep voltammetry (LSV)	Au nanoparticle		(80)
	Differential pulse voltammetry (DPV)	Molybdenum selenide-graphene composites		(81)
	differential pulse voltammetry (DPV)	Au nanoparticle		(82)
	Fluorescence resonance energy transfer (FRET)	poly-L-lysine (PLL)-coated Au nanocomposites	TAMRA	(83)
Carcinoembryonic (CEA)	cyclic voltammograms (CVs): terminal deoxynucleotidyltransferase (TdT)	Au nanoparticle electrode		(84)
	CA ,chronoamperometry	Platinum electrode, and an Ag/AgCl electrode		
	Cyclic voltammetry (CV)/SWV ,square wave voltammetry	Au nanoparticle (AuNPs)	rolling circle amplification (RCA)	(85)
	Photoelectrochemical (PEC)	CdS/TiO ₂ /ITO PEC electrode		(86)
	Electrochemiluminescence	ZnS-CdS/MoS ₂ /glass carbon electrode		(87)
	Fluorescence	AuNPs	AgNCs	(88)
HER2	Voltammetric electrochemical impedance spectroscopy (EIS)/ differential pulse voltammetry (DPV)	Graphene oxide (GO) reduced graphene oxide-chitosan (rGO-Chit)		(89)
	Differential pulse voltammetry (DPV)	Au nanoparticles	ferrocene-labeled DNA/Au nanospheres (FcNS)	(90)
	Non-Faradic impedance spectroscopy (nFIS)	Capacitor microelectrodes		(91)
HepG2	Impedimetric Electrochemical impedance spectroscopy (EIS)/ cyclic voltammograms (CVs)	Au nanoparticles gold nanoparticles (AuNPs) modified the glassy carbon electrode (GCE) surface	(Fe ₃ O ₄ /MnO ₂ /Au@Pd)	(92)
	Differential pulse voltammetry (DPV)	HRP and platinum nanoparticles (PtNPs)		(93)
	Differential pulse voltammetry (DPV)	HRP and MIL-101@AuNPs		(94)

Table 1.(continued)

Target	Transducer	Electrode/ Nanoparticle	Aptamer-label	Refs
MCF-7	Voltammetric Electrochemical impedance spectroscopy (EIS)/ cyclic voltammograms (CVs)	Au nanoparticles/graphene oxide		(95)
	Fluorescence	Graphene oxide (GO)	Quantum dots coated Silica nanoparticles	(96)
	Chronoamperometry (CA)	Au nanoparticles		(97)
K562 leukemia cells	Voltammetric Electrochemical impedance spectroscopy (EIS)/ differential pulse voltammetry (DPV)	Magnetic nanoparticles		(98)
	Voltammetric Electrochemical impedance spectroscopy (EIS)/ cyclic voltammograms (CVs)	Hemin/RGO/Au Nanoflower		(99)
	Fluorescence	Graphene oxide (GO)	Quantum dots coated Silica nanoparticles	(96)
HL-60 cells	Electrochemiluminescence	Au nanoparticles/ Graphene/ Cs ITO glass (Au NPs-GA-CS/ITO)		(100)
	Fluorescence	Graphene oxide (GO)	Quantum dots coated Silica nanoparticles	(96)
CD44	Fluorescence	GO/Au nanoparticles		(101)
hepatoma SMMC-7721 cell	Surface Plasmon Resonance	Au nanoparticles	Magnetic nanoparticles	(102)

4.3. Colorimetric aptamer-based biosensors

There are a few recent studies on developing colorimetric aptamer-based biosensors for cancer biomarker recognition. For instance, in 2020, Dong *et al.* developed a highly sensitive colorimetric aptasensor against the VEGF₁₆₅ in human serum (112). Also in another recent study, Heydari Shayesteh and Ghavami established a label-free colorimetric aptamer-based biosensor for highly sensitive determination of PSA using gold nanoparticles and a cationic polymer (113). Xu *et al.* developed a colorimetric aptasensor against K-Ras, which showed a wide linear range (0.01-150 nM) and the detection limit of 10 pM (114). In another study, Ahirwar *et al.* could successfully establish a nanoparticle-based colorimetric aptasensor recognizing the human estrogen receptor alpha in breast cancer (115).

5. CONCLUSION

Application of aptamers in cancer diagnostic has been studied for a long time and developed to meet the urgent need of an authentic probe in various detection approaches. Based on the distinctive advantages of nucleotide aptamers

compared to antibodies including higher environmental stability (for all purposes), better tumor penetration properties (for aptahistochemistry), easier chemical modification (for all methods using labeled aptamers like fluorescent-aptamers), and the capability of conformational change for switchable systems (especially for biosensors), aptamers are now considered as promising tools for cancer diagnostics. Also unlike antibodies, label-free oligonucleotide aptamers could be simply quantified using qRT-PCR as an affordable quantifying approach. However, the *in vitro* application of aptamers is more applicable since oligonucleotides would be degraded by various nucleases available in living systems. Various types of oligonucleotide aptamers have been successfully isolated and employed in numerous cancer biorecognition strategies *in vitro*, including tissue-marker detection, enzyme-linked assay, flow cytometry, and biosensing. Various chemical and reporting labels like fluorophores, biotin, HRP, *etc.* leads to utilizing biomarker specific aptamers as detection moiety of various cancer diagnostic strategies. In particular, some multifunctional

nanoparticle-based labels are developed for enhancing detection capability. In this study, the progress of aptamer applications in the field of cancer detection is summarized over recent years. Aptamer-based strategies are becoming gradually more common. As shown in Fig. 1, the aptamer-based investigation is a high-speed growing field, indicating the special place of this method in future studies. Although, the number of aptamer-guided biosensing studies has suddenly elevated since 2012, but its commercial applications are limited. The investigations will lead to improved existing aptamer-based strategies for biosensing and bioimaging, and promising better performance in the future. Until quite recently, the practical properties of two promising aptamer-based methods in cancer diagnostics are being evaluated in clinical trials.

6. ACKNOWLEDGMENTS

The study described here was financially supported by Isfahan University of Medical Science under the Grant No. 396391 and by the Biotechnology Development Council of the Islamic Republic of Iran under the Grant No. 960304.

7. CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest for this study.

8. AUTHORS' CONTRIBUTION

All authors contributed equally in this work.

9. REFERENCES

- Floor SL, Dumont JE, Maenhaut C, Raspe E. Hallmarks of cancer: of all cancer cells, all the time? *Trends Mol Med*. 2012;18(9):509-515. DOI: 10.1016/j.molmed.2012.06.005.
- Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. *Curr Opin Genet Dev*. 2012;22(1):50-55. DOI: 10.1016/j.gde.2012.02.008.
- Henry NL, Hayes DF. Cancer biomarkers. *Mol Oncol*. 2012;6(2):140-146. DOI: 10.1016/j.molonc.2012.01.010
- Ilgu M, Nilsen-Hamilton M. Aptamers in analytics. *Analyst*. 2016;141(5):1551-1568. DOI: 10.1039/c5an01824b.
- Mokhtarzadeh A, Tabarzad M, Ranjbari J, Guardia de la M, Hejazi M, Ramezani M. Aptamers as smart ligands for nano-carriers targeting. *Trends Analyt Chem*. 2016;82:316-327. DOI: 10.1016/j.trac.2016.06.018.
- Mirian M, Khanahmad H, Darzi L, Salehi M, Sadeghi-Aliabadi H. Oligonucleotide aptamers: potential novel molecules against viral hepatitis. *Res Pharm Sci*. 2017;12(2):88-98. DOI: 10.4103/1735-5362.202447.
- Vallian S, Khazaei MR. Medical applications of aptamers. *Res Pharm Sci*. 2007;2(2):59-66.
- Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science*. 1990;249(4968):505-510. DOI: 10.1126/science.2200121.
- Hermann T, Patel DJ. Adaptive recognition by nucleic acid aptamers. *Science*. 2000;287(5454):820-825. DOI: 10.1126/science.287.5454.820.
- Jamalvandi M, Khanahmad H, Irani S, Bastaminezhad S. Selection and characterization of single-stranded DNA aptamers against interleukin-5. *Res Pharm Sci*. 2019;14(6):515-523. DOI: 10.4103/1735-5362.272560.
- Taghavi S, Ramezani M, Abnous K. Preparation and evaluation of transfection efficiency of binding carbon nanotube to aptamer in breast cancer cell line. *Res Pharm Sci*. 2012;7(5):1000.
- Boshtam M, Asgary S, Kouhpayeh S, Shariati L, Khanahmad H. Aptamers against pro-and anti-inflammatory cytokines: a review. *Inflammation*. 2017;40(1):340-349. DOI: 10.1007/s10753-016-0477-1.
- Fatahi A, Rahimmanesh I, Mirian M, Rohani F, Boshtam M, Gheibi A, *et al*. Construction and characterization of human embryonic kidney-(HEK)-293T cell overexpressing truncated $\alpha 4$ integrin. *Res Pharm Sci*. 2018;13(4):353-359. DOI: 10.4103/1735-5362.235162.
- Xu Y, Yang L, Ye X, He P, Fang Y. An aptamer-based protein biosensor by detecting the amplified impedance signal. *Electroanalysis*. 2006;18(15):1449-1456. DOI: 10.1002/elan.200603566.
- Lai RY, Plaxco KW, Heeger AJ. Aptamer-based electrochemical detection of picomolar platelet-derived growth factor directly in blood serum. *Anal Chem*. 2007;79(1):229-233. DOI: 10.1021/ac061592s.
- Liss M, Petersen B, Wolf H, Prohaska E. An aptamer-based quartz crystal protein biosensor. *Anal Chem*. 2002;74(17):4488-4495. DOI: 10.1021/ac011294p.
- Babendure JR, Adams SR, Tsien RY. Aptamers switch on fluorescence of triphenylmethane dyes. *J Am Chem Soc*. 2003;125(48):14716-14717. DOI: 10.1021/ja037994o.
- Bhalla N, Jolly P, Formisano N, Estrela P. Introduction to biosensors. *Essays Biochem*. 2016;60(1):1-8. DOI: 10.1042/EBC20150001.
- Tothill IE, editor *Biosensors for cancer markers diagnosis*. *Semin Cell Dev Biol*. 2009;20(1):55-62. DOI: 10.1016/j.semcdb.2009.01.015.

20. Zeng Z, Zhang P, Zhao N, Sheehan AM, Tung CH, Chang CC, et al. Using oligonucleotide aptamer probes for immunostaining of formalin-fixed and paraffin-embedded tissues. *Mod Pathol*. 2010;23(12):1553-1558. DOI: 10.1038/modpathol.2010.151.
21. Han ME, Baek S, Kim HJ, Lee JH, Ryu SH, Oh SO. Development of an aptamer-conjugated fluorescent nanoprobe for MMP2. *Nanoscale Res Lett*. 2014;9(1):104-110. DOI: 10.1186/1556-276X-9-104.
22. Wang Y, Luo Y, Bing T, Chen Z, Lu M, Zhang N, et al. DNA aptamer evolved by cell-SELEX for recognition of prostate cancer. *PLoS One*. 2014;9(6): e100243,1-10. DOI: 10.1371/journal.pone.0100243.
23. Duan M, Long Y, Yang C, Wu X, Sun Y, Li J, et al. Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging. *Oncotarget*. 2016;7(24):36436-36446. DOI: 10.18632/oncotarget.9262.
24. Huang ZX, Xie Q, Guo QP, Wang KM, Meng XX, Yuan BY, et al. DNA aptamer selected for specific recognition of prostate cancer cells and clinical tissues. *Chinese Chem Lett*. 2017;28(6):1252-1257. DOI: 10.1016/j.ccllet.2017.01.002.
25. Stuart CH, Riley KR, Boyacioglu O, Herpai DM, Debinski W, Qasem S, et al. Selection of a novel aptamer against vitronectin using capillary electrophoresis and next generation sequencing. *Mol Ther Nucleic Acids*. 2016;5(11):e386,1-9. DOI: 10.1038/mtna.2016.91.
26. Ahirwar R, Vellarikkal SK, Sett A, Sivasubbu S, Scaria V, Bora U, et al. Aptamer-assisted detection of the altered expression of estrogen receptor alpha in human breast cancer. *PloS One*. 2016;11(4):e0153001,1-17. DOI: 10.1371/journal.pone.0153001.
27. Yuan B, Jiang X, Chen Y, Guo Q, Wang K, Meng X, et al. Metastatic cancer cell and tissue-specific fluorescence imaging using a new DNA aptamer developed by Cell-SELEX. *Talanta*. 2017;170:56-62. DOI: 10.1016/j.talanta.2017.03.094.
28. In: Randall RL, editor. *Metastatic bone disease. An Integrated Approach to Patient Care*. 1^{ed}. Springer; 2016. pp: 110-117.
29. Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications after systematic, random, and image-guided prostate biopsy. *Eur Urol*. 2017;71(3):353-365. DOI: 10.1016/j.eururo.2016.08.004.
30. Fumagalli C, Bianchi F, Raviele PR, Vacirca D, Bertalot G, Rampinelli C, et al. Circulating and tissue biomarkers in early-stage non-small cell lung cancer. *Ecancermedalscience*. 2017;11:717-726. DOI: 10.3332/ecancer.2017.717.
31. Konforte D, Diamandis EP. Is early detection of cancer with circulating biomarkers feasible? *Clin Chem*. 2013;59(1):35-37. DOI: 10.1373/clinchem.2012.184903.
32. Arya M, Shergill I, Williamson M, Gommersall L, Arya N, Patel HR. Basic principles of real-time quantitative PCR. *Expert Rev Mol Diagn*. 2005;5(2):209-219. DOI: 10.1586/14737159.5.2.209.
33. Gheysarzadeh A, Bakhtiari H, Ansari A, Emami Razavi A, Emami MH, Mofid MR. The insulin-like growth factor binding protein-3 and its death receptor in pancreatic ductal adenocarcinoma poor prognosis. *J Cell Physiol*. 2019;234(12):1-10. DOI: 10.1002/jcp.28922.
34. Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonák J, Lind K, et al. The real-time polymerase chain reaction. *Mol Aspects Med*. 2006;27(2-3):95-125. DOI: 10.1016/j.mam.2005.12.007.
35. Moreno M, Fernández-Algar M, Fernández-Chamorro J, Ramajo J, Martínez-Salas E, Briones C. A combined ELONA-(RT)qPCR approach for characterizing DNA and RNA aptamers selected against PCBP-2. *Molecules*. 2019;24(7):1213-1228. DOI: 10.3390/molecules24071213.
36. Dos Santos VCF, Almeida NBF, de Sousa TASL, Araujo END, de Andrade ASR, Plentz F. Real-time PCR for direct aptamer quantification on functionalized graphene surfaces. *Sci Rep*. 2019;9(1):19311-19318. DOI: 10.1038/s41598-019-55892-3.
37. Kouhpayeh S, Hejazi Z, Khanahmad H, Rezaei A. Real-time PCR: an appropriate approach to confirm ssDNA generation from PCR product in SELEX process. *Iran J Biotechnol*. 2017;15(2):143-148. DOI: 10.15171/ijb.1550.
38. Savory N, Nzakizwanayo J, Abe K, Yoshida W, Ferri S, Dedi C, et al. Selection of DNA aptamers against uropathogenic *Escherichia coli* NSM59 by quantitative PCR controlled Cell-SELEX. *J Microbiol Methods*. 2014;104:94-100. DOI: 10.1016/j.mimet.2014.06.016.
39. Ouellet E, Foley JH, Conway EM, Haynes C. Hi-Fi SELEX: a high-fidelity digital-PCR based therapeutic aptamer discovery platform. *Biotechnol Bioeng*. 2015;112(8):1506-1522. DOI: 10.1002/bit.25581.
40. Li K, Xiu CL, Gao LM, Liang HG, Xu SF, Shi M, et al. Screening of specific nucleic acid aptamers binding tumor markers in the serum of the lung cancer patients and identification of their activities. *Tumour Biol*. 2017;39(7):1010428317717123,1-7. DOI: 10.1177/1010428317717123.
41. Li K, Qi L, Gao L, Shi M, Li J, Liu Z, et al. Selection and preliminary application of a single stranded DNA aptamer targeting colorectal cancer serum. *RSC Adv*. 2019;9(66):38867-38876. DOI: 10.1039/C9RA04777H.
42. Wu ZS, Guo MM, Zhang SB, Chen CR, Jiang JH, Shen GL, et al. Reusable electrochemical sensing platform for highly sensitive detection of small molecules based on structure-switching signaling aptamers. *Anal Chem*. 2007;79(7):2933-2939. DOI: 10.1021/ac0622936.
43. Lee KA, Ahn JY, Lee SH, Sekhon SS, Kim DG, Min J, et al. Aptamer-based sandwich assay and its clinical outlook for detecting lipocalin-2 in hepatocellular carcinoma (HCC). *Sci Rep*. 2015;5:10897-10909. DOI: 10.1038/srep10897.
44. Ferreira C, Papamichael K, Guilbault G, Schwarzacher T, Garipey J, Missailidis S. DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours. *Anal Bioanal Chem*. 2008;390(4):1039-1050. DOI: 10.1007/s00216-007-1470-1.

45. Jolly P, Damborsky P, Madaboosi N, Soares RR, Chu V, Conde JP, *et al.* DNA aptamer-based sandwich microfluidic assays for dual quantification and multi-glycan profiling of cancer biomarkers. *Biosens Bioelectron.* 2015;79:313-319. DOI: 10.1016/j.bios.2015.12.058.
46. Zhu X, Yang J, Liu M, Wu Y, Shen Z, Li G. Sensitive detection of human breast cancer cells based on aptamer-cell-aptamer sandwich architecture. *Anal Chim Acta.* 2013;764:59-63. DOI: 10.1016/j.aca.2012.12.024.
47. Kavosi B, Salimi A, Hallaj R, Moradi F. Ultrasensitive electrochemical immunosensor for PSA biomarker detection in prostate cancer cells using gold nanoparticles/PAMAM dendrimer loaded with enzyme linked aptamer as integrated triple signal amplification strategy. *Biosens Bioelectron.* 2015;74:915-923. DOI: 10.1016/j.bios.2015.07.064.
48. Haghghi M, Khanahmad H, Palizban A. Selection and characterization of single-stranded DNA aptamers binding human B-cell surface protein CD20 by cell-SELEX. *Molecules.* 2018;23(4):E715,1-13. DOI: 10.3390/molecules23040715.
49. Yang M, Jiang G, Li W, Qiu K, Zhang M, Carter CM, *et al.* Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery. *J Hematol Oncol.* 2014;7:5-18. DOI: 10.1186/1756-8722-7-5.
50. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, *et al.* Aptamers evolved from live cells as effective molecular probes for cancer study. *Proc Natl Acad Sci U S A.* 2006;103(32):11838-11843. DOI: 10.1073/pnas.0602615103.
51. Mallikaratchy PR, Ruggiero A, Gardner JR, Kuryavyy V, Maguire WF, Heaney ML, *et al.* A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. *Nucleic Acids Res.* 2011;39(6):2458-2469. DOI: 10.1093/nar/gkq996.
52. Sefah K, Tang ZW, Shangguan DH, Chen H, Lopez-Colon D, Li Y, *et al.* Molecular recognition of acute myeloid leukemia using aptamers. *Leukemia.* 2009;23(2):235-244. DOI: 10.1038/leu.2008.335.
53. Tan J, Yang N, Hu Z, Su J, Zhong J, Yang Y, *et al.* Aptamer-functionalized fluorescent silica nanoparticles for highly sensitive detection of leukemia cells. *Nanoscale Res Lett.* 2016;11(1):298-306. DOI: 10.1186/s11671-016-1512-8.
54. Zhang P, Zhao N, Zeng Z, Feng Y, Tung CH, Chang CC, *et al.* Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells. *Lab Invest.* 2009;89(12):1423-1432. DOI: 10.1038/labinvest.2009.113.
55. Tsai SC, Hung LY, Lee GB. An integrated microfluidic system for the isolation and detection of ovarian circulating tumor cells using cell selection and enrichment methods. *Biomicrofluidics.* 2017;11(3):034122,1-11. DOI: 10.1063/1.4991476.
56. Zheng F, Cheng Y, Wang J, Lu J, Zhang B, Zhao Y, *et al.* Aptamer-functionalized barcode particles for the capture and detection of multiple types of circulating tumor cells. *Adv Mater.* 2014;26(43):7333-7338. DOI: 10.1002/adma.201403530.
57. Zamay GS, Kolovskaya OS, Zamay TN, Glazyrin YE, Krat AV, Zubkova O, *et al.* Aptamers selected to postoperative lung adenocarcinoma detect circulating tumor cells in human blood. *Mol Ther.* 2015;23(9):1486-1496. DOI: 10.1038/mt.2015.108.
58. Li S, Chen N, Zhang Z, Wang Y. Endonuclease-responsive aptamer-functionalized hydrogel coating for sequential catch and release of cancer cells. *Biomaterials.* 2013;34(2):460-469. DOI: 10.1016/j.biomaterials.2012.09.040.
59. Zhao L, Tang C, Xu L, Zhang Z, Li X, Hu H, *et al.* Enhanced and differential capture of circulating tumor cells from lung cancer patients by microfluidic assays using aptamer cocktail. *Small.* 2016;12(8):1072-1081. DOI: 10.1002/smll.201503188.
60. Topkaya SN, Azimzadeh M, Ozsoz M. Electrochemical biosensors for cancer biomarkers detection: recent advances and challenges. *Electroanalysis.* 2016;28(7):1402-1419. DOI: 10.1002/elan.201501174.
61. Zhou J, Cheng K, Chen X, Yang R, Lu M, Ming L, *et al.* Determination of soluble CD44 in serum by using a label-free aptamer based electrochemical impedance biosensor. *Analyst.* 2020;145(2):460-465. DOI: 10.1039/C9AN01764J.
62. Safavipour M, Kharaziha M, Amjadi E, Karimzadeh F, Allafchian A. TiO₂ nanotubes/reduced GO nanoparticles for sensitive detection of breast cancer cells and photothermal performance. *Talanta.* 2020;208:120369-120370. DOI:10.1016/j.talanta.2019.120366.
63. Arya SK, Zhuravskiy P, Jolly P, Batistuti MR, Mulato M, Estrela P. Capacitive aptasensor based on interdigitated electrode for breast cancer detection in undiluted human serum. *Biosens Bioelectron.* 2018;102:106-112. DOI: 10.1016/j.bios.2017.11.013.
64. Yazdanparast S, Benvidi A, Banaei M, Nikukar H, Tezerjani MD, Azimzadeh M. Dual-aptamer based electrochemical sandwich biosensor for MCF-7 human breast cancer cells using silver nanoparticle labels and a poly(glutamic acid)/MWNT nanocomposite. *Mikrochim Acta.* 2018;185(9):405. DOI: 10.1007/s00604-018-2918-z.
65. Motaghi H, Ziyadeh S, Mehrgardi MA, Kajani AA, Bordbar AK. Electrochemiluminescence detection of human breast cancer cells using aptamer modified bipolar electrode mounted into 3D printed microchannel. *Biosens Bioelectron.* 2018;118:217-223. DOI: 10.1016/j.bios.2018.07.066.
66. Nie Y, Yuan X, Zhang P, Chai YQ, Yuan R. Versatile and ultrasensitive electrochemiluminescence biosensor for biomarker detection based on nonenzymatic amplification and aptamer-triggered emitter release. *Anal Chem.* 2019;91(5):3452-3458. DOI: 10.1021/acs.analchem.8b05001.
67. Tabrizi MA, Shamsipur M, Saber R, Sarkar S. Isolation of HL-60 cancer cells from the human serum sample using MnO₂-PEI/Ni/Au/aptamer as a novel nanomotor and electrochemical determination of thereof

- by aptamer/gold nanoparticles-poly(3,4-ethylene dioxithiophene) modified GC electrode. *Biosens Bioelectron.* 2018;110:141-146. DOI: 10.1016/j.bios.2018.03.034.
68. Song S, Na J, Jang M, Lee H, Lee HS, Lim YB, *et al.* A CMOS VEGF sensor for cancer diagnosis using a peptide aptamer-based functionalized microneedle. *IEEE Trans Biomed Circuits Syst.* 2019;13(6):1288-1299. DOI: 10.1109/TBCAS.2019.2954846.
69. Ou D, Sun D, Lin X, Liang Z, Zhong Y, Chen Z. A dual-aptamer-based biosensor for specific detection of breast cancer biomarker HER2 *via* flower-like nanozymes and DNA nanostructures. *J Mater Chem B.* 2019;7(23):3661-3669. DOI: 10.1039/C9TB00472F.
70. Hasanzadeh M, Razmi N, Mokhtarzadeh A, Shadjou N, Mahboob S. Aptamer based assay of plated-derived growth factor in unprocessed human plasma sample and MCF-7 breast cancer cell lysates using gold nanoparticle supported α -cyclodextrin. *Int J Biol Macromol.* 2018;108:69-80. DOI: 10.1016/j.ijbiomac.2017.11.149.
71. Li Y, Zhang Y, Zhao M, Zhou Q, Wang L, Wang H, *et al.* A simple aptamer-functionalized gold nanorods based biosensor for the sensitive detection of MCF-7 breast cancer cells. *Chem Commun (Camb).* 2016;52(20):3959-3961. DOI: 10.1039/c6cc01014h.
72. Li Y, Wang X, Zhou Q, Zhang Y, Zhan L. A simple aptamer-functionalized gold nanorods based biosensor for early diagnosis of breast cancer in needle biopsy. *Nanomedicine.* 2016;20(12):477.
73. Chen H, Hou Y, Ye Z, Wang H, Koh K, Shen Z, *et al.* Label-free surface plasmon resonance cytosensor for breast cancer cell detection based on nano-conjugation of monodisperse magnetic nanoparticle and folic acid. *Sens Actuators B Chem.* 2014;201:433-438. DOI: 10.1016/j.snb.2014.04.040.
74. Li SK, Chen AY, Chai YQ, Yuan R, Zhuo Y. Electrochemiluminescence aptasensor based on cascading amplification of nicking endonuclease-assisted target recycling and rolling circle amplifications for mucin 1 detection. *Electrochim Acta.* 2016;212:767-774. DOI: 10.1016/j.electacta.2016.07.074.
75. Lin C, Zheng H, Huang Y, Chen Z, Luo F, Wang J, *et al.* Homogeneous electrochemical aptasensor for mucin 1 detection based on exonuclease I-assisted target recycling amplification strategy. *Biosens Bioelectron.* 2018;117:474-479. DOI: 10.1016/j.bios.2018.06.056.
76. Chen H, Hou Y, Qi F, Zhang J, Koh K, Shen Z, *et al.* Detection of vascular endothelial growth factor based on rolling circle amplification as a means of signal enhancement in surface plasmon resonance. *Biosens Bioelectron.* 2014;61:83-87. DOI: 10.1016/j.bios.2014.05.005.
77. Fu XM, Liu ZJ, Cai SX, Zhao YP, Wu DZ, Li CY, *et al.* Electrochemical aptasensor for the detection of vascular endothelial growth factor (VEGF) based on DNA-templated Ag/Pt bimetallic nanoclusters. *Chinese Chem Lett.* 2016;27(6):920-926. DOI: 10.1016/j.ccllet.2016.04.014.
78. Zhang H, Li M, Li C, Guo Z, Dong H, Wu P, *et al.* G-quadruplex DNAzyme-based electrochemiluminescence biosensing strategy for VEGF165 detection: combination of aptamer-target recognition and T7 exonuclease-assisted cycling signal amplification. *Biosens Bioelectron.* 2015;74:98-103. DOI: 10.1016/j.bios.2015.05.069.
79. Jun J, Lee JS, Shin DH, Jang J. Aptamer-functionalized hybrid carbon nanofiber FET-type electrode for a highly sensitive and selective platelet-derived growth factor biosensor. *ACS Appl Mater Interfaces.* 2014;6(16):13859-13865. DOI: 10.1021/am5032693.
80. Wang Q, Zheng H, Gao X, Lin Z, Chen G. A label-free ultrasensitive electrochemical aptameric recognition system for protein assay based on hyperbranched rolling circle amplification. *Chem Commun (Camb).* 2013;49(97):11418-11420. DOI: 10.1039/c3cc46274a.
81. Huang KJ, Shuai HL, Zhang JZ. Ultrasensitive sensing platform for platelet-derived growth factor BB detection based on layered molybdenum selenide-graphene composites and Exonuclease III assisted signal amplification. *Biosens Bioelectron.* 2016;77:69-75. DOI: 10.1016/j.bios.2015.09.026.
82. Yu Y, Su G, Zhu H, Zhu Q, Chen Y, Xu B, *et al.* Proximity hybridization-mediated isothermal exponential amplification for ultrasensitive electrochemical protein detection. *Int J Nanomedicine.* 2017;12:5903-5914. DOI: 10.2147/IJN.S142015.
83. Zhu D, Yang RX, Tang YP, Li W, Miao ZY, Hu Y, *et al.* Robust nanoplasmonic substrates for aptamer macroarrays with single-step detection of PDGF-BB. *Biosens Bioelectron.* 2016;85:429-436. DOI: 10.1016/j.bios.2016.05.039.
84. Wang P, Wan Y, Deng S, Yang S, Su Y, Fan C, *et al.* Aptamer-initiated on-particle template-independent enzymatic polymerization (aptamer-OTEP) for electrochemical analysis of tumor biomarkers. *Biosens Bioelectron.* 2016;86:536-541. DOI: 10.1016/j.bios.2016.07.025.
85. Jiang W, Liu L, Zhang L, Guo Q, Cui Y, Yang M. Sensitive immunosensing of the carcinoembryonic antigen utilizing aptamer-based *in-situ* formation of a redox-active heteropolyacid and rolling circle amplification. *Microchim Acta.* 2017;184(12):4757-4763. DOI: 10.1007/s00604-017-2522-7.
86. Ge L, Wang W, Hou T, Li F. A versatile immobilization-free photoelectrochemical biosensor for ultrasensitive detection of cancer biomarker based on enzyme-free cascaded quadratic amplification strategy. *Biosens Bioelectron.* 2016;77:220-226. DOI: 10.1016/j.bios.2015.09.041.
87. Wang YL, Cao JT, Chen YH, Liu YM. A label-free electrochemiluminescence aptasensor for carcinoembryonic antigen detection based on electrodeposited ZnS-CdS on MoS₂ decorated electrode. *Anal Methods.* 2016;8(26):5242-5247. DOI: 10.1039/C6AY01114D.
88. Yang X, Zhuo Y, Zhu S, Luo Y, Feng Y, Xu Y. Selectively assaying CEA based on a creative strategy of gold nanoparticles enhancing silver nanoclusters'

- fluorescence. *Biosens Bioelectron.* 2015;64:345-351. DOI: 10.1016/j.bios.2014.09.029.
89. Tabasi A, Noorbakhsh A, Sharifi E. Reduced graphene oxide-chitosan-aptamer interface as new platform for ultrasensitive detection of human epidermal growth factor receptor 2. *Biosens Bioelectron.* 2017;95:117-123. DOI: 10.1016/j.bios.2017.04.020.
 90. Yang S, You M, Zhang F, Wang Q, He P. A sensitive electrochemical aptasensing platform based on exonuclease recycling amplification and host-guest recognition for detection of breast cancer biomarker HER2. *Sens Actuators B Chem.* 2018;258:796-802. DOI: 10.1016/j.snb.2017.11.119.
 91. Qureshi A, Gurbuz Y, Niazi JH. Label-free capacitance based aptasensor platform for the detection of HER2/ErbB2 cancer biomarker in serum. *Sens Actuators B Chem.* 2015;220:1145-51. DOI: 10.1016/j.snb.2015.06.094.
 92. Sun D, Lu J, Zhong Y, Yu Y, Wang Y, Zhang B, *et al.* Sensitive electrochemical aptamer cytosensor for highly specific detection of cancer cells based on the hybrid nanoelectrocatalysts and enzyme for signal amplification. *Biosens Bioelectron.* 2016;75:301-307. DOI: 10.1016/j.bios.2015.08.056.
 93. Sun D, Lu J, Luo Z, Zhang L, Liu P, Chen Z. Competitive electrochemical platform for ultrasensitive cytosensing of liver cancer cells by using nanotetrahedra structure with rolling circle amplification. *Biosens Bioelectron.* 2018;120:8-14. DOI: 10.1016/j.bios.2018.08.002.
 94. Chen D, Sun D, Wang Z, Qin W, Chen L, Zhou L, *et al.* A DNA nanostructured aptasensor for the sensitive electrochemical detection of HepG2 cells based on multibranch hybridization chain reaction amplification strategy. *Biosens Bioelectron.* 2018;117:416-421. DOI: 10.1016/j.bios.2018.06.041.
 95. Wang K, He MQ, Zhai FH, He RH, Yu YL. A novel electrochemical biosensor based on polyadenine modified aptamer for label-free and ultrasensitive detection of human breast cancer cells. *Talanta.* 2017;166:87-92. DOI: 10.1016/j.talanta.2017.01.052.
 96. Liang L, Su M, Li L, Lan F, Yang G, Ge S, *et al.* Aptamer-based fluorescent and visual biosensor for multiplexed monitoring of cancer cells in microfluidic paper-based analytical devices. *Sens Actuators B Chem.* 2016;229:347-354. DOI: 10.1016/j.snb.2016.01.137.
 97. Zhou G, Lin M, Song P, Chen X, Chao J, Wang L, *et al.* Multivalent capture and detection of cancer cells with DNA nanostructured biosensors and multibranch hybridization chain reaction amplification. *Anal Chem.* 2014;86(15):7843-7848. DOI: 10.1021/ac502276w.
 98. Khoshfetrat SM, Mehrgardi MA. Amplified detection of leukemia cancer cells using an aptamer-conjugated gold-coated magnetic nanoparticles on a nitrogen-doped graphene modified electrode. *Bioelectrochemistry.* 2017;114:24-32. DOI: 10.1016/j.bioelechem.2016.12.001.
 99. Liu J, Cui M, Niu L, Zhou H, Zhang S. Enhanced peroxidase-like properties of graphene-hemin-composite decorated with Au nanoflowers as electrochemical aptamer biosensor for the detection of K562 leukemia cancer cells. *Chemistry.* 2016;22(50):18001-18008. DOI: 10.1002/chem.201604354.
 100. Feng QM, Liu Z, Chen HY, Xu JJ. Paper-based electrochemiluminescence biosensor for cancer cell detection. *Electrochem Commun.* 2014;49:88-92. DOI: 10.1016/j.elecom.2014.10.015.
 101. Jeong HY, Baek SH, Chang SJ, Cheon SA, Park TJ. Robust fluorescence sensing platform for detection of CD44 cells based on graphene oxide/gold nanoparticles. *Colloids Surf B Biointerfaces.* 2015;135:309-315. DOI: 10.1016/j.colsurfb.2015.07.083.
 102. Liu R, Wang Q, Li Q, Yang X, Wang K, Nie W. Surface plasmon resonance biosensor for sensitive detection of microRNA and cancer cell using multiple signal amplification strategy. *Biosens Bioelectron.* 2017;87:433-438. DOI: 10.1016/j.bios.2016.08.090.
 103. Liu G, Mao X, Phillips JA, Xu H, Tan W, Zeng L. Aptamer-nanoparticle strip biosensor for sensitive detection of cancer cells. *Anal Chem.* 2009;81(24):10013-10018. DOI: 10.1021/ac901889s.
 104. Bayat P, Taghdisi SM, Rafatpanah H, Abnous K, Ramezani M. *In vitro* selection of CD70 binding aptamer and its application in a biosensor design for sensitive detection of SKOV-3 ovarian cells. *Talanta.* 2019;194:399-405. DOI: 10.1016/j.talanta.2018.10.063.
 105. Gedi V, Song CK, Kim GB, Lee JO, Oh E, Shin BS, *et al.* Sensitive on-chip detection of cancer antigen 125 using a DNA aptamer/carbon nanotube network platform. *Sens Actuators B Chem.* 2018;256:89-97. DOI: 10.1016/j.snb.2017.10.049.
 106. Gong S, Ren H, Lin C, Hu P, Tian R, Liu Z, *et al.* Immunochromatographic strip biosensor for the rapid detection of N-glycolylneuraminic acid based on aptamer-conjugated nanoparticle. *Anal Biochem.* 2018;561:52-58. DOI: 10.1016/j.ab.2018.07.017.
 107. Liu J, Zhang Y, Zhao Q, Situ B, Zhao J, Luo S, *et al.* Bifunctional aptamer-mediated catalytic hairpin assembly for the sensitive and homogenous detection of rare cancer cells. *Anal Chim Acta.* 2018;1029:58-64. DOI: 10.1016/j.aca.2018.04.068.
 108. Luo Z, Xu Y, Huang Z, Chen J, Wang X, Li D, *et al.* A rapid, adaptive DNA biosensor based on molecular beacon-concatenated dual signal amplification strategies for ultrasensitive detection of p53 gene and cancer cells. *Talanta.* 2020;210:120638-120645. DOI: 10.1016/j.talanta.2019.120638.
 109. Mazhabi RM, Ge L, Jiang H, Wang X. A label-free aptamer-based cytosensor for specific cervical cancer HeLa cell recognition through a g-C₃N₄-AgI/ITO photoelectrode. *J Mater Chem B.* 2018;6(31):5039-5049. DOI: 10.1039/C8TB01067F.
 110. Zhao L, Cheng M, Liu G, Lu H, Gao Y, Yan X, *et al.* A fluorescent biosensor based on molybdenum disulfide nanosheets and protein aptamer for sensitive detection of carcinoembryonic antigen. *Sens Actuators B Chem.* 2018;273:185-190. DOI: 10.1016/j.snb.2018.06.004.
 111. Molecular Biosensors for Detection of Bladder Cancer. Available from: <https://clinicaltrials.gov/ct2/show/NCT02957370?term=aptamer&draw=2&rank=7>.

112. Dong J, He L, Wang Y, Yu F, Yu S, Liu L, *et al.* A highly sensitive colorimetric aptasensor for the detection of the vascular endothelial growth factor in human serum. *Spectrochim Acta A Mol Biomol Spectrosc.* 2020;226:117622-117627.
DOI: 10.1016/j.saa.2019.117622.
113. Shayesteh OH, Ghavami R. A novel label-free colorimetric aptasensor for sensitive determination of PSA biomarker using gold nanoparticles and a cationic polymer in human serum. *Spectrochim Acta A Mol Biomol Spectrosc.* 2020;226:117644-117650.
DOI: 10.1016/j.saa.2019.117644.
114. Xu H, Wu D, Li CQ, Lu Z, Liao XY, Huang J, *et al.* Label-free colorimetric detection of cancer related gene based on two-step amplification of molecular machine. *Biosens Bioelectron.* 2017;90:314-320.
DOI: 10.1016/j.bios.2016.12.003.
115. Ahirwar R, Nahar P. Development of a label-free gold nanoparticle-based colorimetric aptasensor for detection of human estrogen receptor alpha. *Anal Bioanal Chem.* 2016;408(1):327-332.
DOI: 10.1007/s00216-015-9090-7.